Charles River Laboratories Inte (CRL)

Charles River Laboratories Inte (Healthcare) achieves an AlphaScore of 46/100 as of 2026-10-11, with a neutral signal and a price of 301.79. Fundamentals show a zero debt-to-equity ratio and a revenue growth of -0.85. A major strength is its completely debt-free balance sheet, evidenced by a debt-to-equity ratio of 0. Conversely, a primary risk is the negative return on equity of -4.56 and a negative net margin of -3.59, revealing current unprofitability.

Written 11/10/2026, 00:42:53 UTC · Snapshot 11/10/2026